Intermountain Healthcare is back at it, this time tackling Type 2 diabetes. The company has partnered with the American Medical Association and Omada Health to…

Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this…

Shares in uniQure briefly hit a new low following a negative knee-jerk reaction to fresh data on its hemophilia B gene therapy.

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

Boston Scientific is snatching up Cosman Medical to get its hands on the company’s radiofrequency ablation systems to expand its neuromodulation portfolio.…

A Cancer Research UK funded study has found an antimalaria drug could reverse tumor hypoxia and complement radiotherapy in killing cancer cells.

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Building on the original 2013 R&D deal between Japan’s Astellas and Cytokinetics, the two have now expanded their initial collab, which will see Astellas…